250 related articles for article (PubMed ID: 32496434)
21. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
22. p16INK4A expression as biomarker for HPV 16-related vulvar neoplasias.
Riethdorf S; Neffen EF; Cviko A; Löning T; Crum CP; Riethdorf L
Hum Pathol; 2004 Dec; 35(12):1477-83. PubMed ID: 15619206
[TBL] [Abstract][Full Text] [Related]
23. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
[TBL] [Abstract][Full Text] [Related]
24. Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma.
Cocks M; Chaux A; Jenson EG; Miller JA; Rodriguez Pena MDC; Tregnago AC; Taheri D; Eich ML; Sharma R; Vang R; Netto GJ
Virchows Arch; 2020 Jul; 477(1):93-102. PubMed ID: 31993774
[TBL] [Abstract][Full Text] [Related]
25. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
26. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
Howitt BE; Sun HH; Roemer MG; Kelley A; Chapuy B; Aviki E; Pak C; Connelly C; Gjini E; Shi Y; Lee L; Viswanathan A; Horowitz N; Neuberg D; Crum CP; Lindeman NL; Kuo F; Ligon AH; Freeman GJ; Hodi FS; Shipp MA; Rodig SJ
JAMA Oncol; 2016 Apr; 2(4):518-22. PubMed ID: 26913631
[TBL] [Abstract][Full Text] [Related]
27. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
Minion LE; Tewari KS
Gynecol Oncol; 2018 Mar; 148(3):609-621. PubMed ID: 29666026
[TBL] [Abstract][Full Text] [Related]
28. MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition.
Friedman LA; Bullock TN; Sloan EA; Ring KL; Mills AM
Mod Pathol; 2021 Mar; 34(3):627-636. PubMed ID: 33011747
[TBL] [Abstract][Full Text] [Related]
29. Human papillomavirus infection and p16(INK4a) protein expression in vulvar intraepithelial neoplasia and invasive squamous cell carcinoma.
Rufforny I; Wilkinson EJ; Liu C; Zhu H; Buteral M; Massoll NA
J Low Genit Tract Dis; 2005 Apr; 9(2):108-13. PubMed ID: 15870532
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva.
Thangarajah F; Morgenstern B; Pahmeyer C; Schiffmann LM; Puppe J; Mallmann P; Hamacher S; Buettner R; Alidousty C; Holz B; Scheel AH; Schultheis AM
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1651-1660. PubMed ID: 30972492
[TBL] [Abstract][Full Text] [Related]
31. PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.
Nagarajan P; El-Hadad C; Gruschkus SK; Ning J; Hudgens CW; Sagiv O; Gross N; Tetzlaff MT; Esmaeli B
Invest Ophthalmol Vis Sci; 2019 May; 60(6):2388-2398. PubMed ID: 31141610
[TBL] [Abstract][Full Text] [Related]
32. A population-based case-control study of genetic variation in cytokine genes associated with risk of cervical and vulvar cancers.
Hardikar S; Johnson LG; Malkki M; Petersdorf EW; Galloway DA; Schwartz SM; Madeleine MM
Gynecol Oncol; 2015 Oct; 139(1):90-6. PubMed ID: 26241630
[TBL] [Abstract][Full Text] [Related]
33. HPV-ISH-Negative Invasive Cervical Squamous Cell Carcinoma: Histologic and Pap Test Results.
Alexander C; White M; Maleki Z; Rodriguez EF
Acta Cytol; 2019; 63(5):417-423. PubMed ID: 31195388
[TBL] [Abstract][Full Text] [Related]
34. p53 mutations and clonality in vulvar carcinomas and squamous hyperplasias: evidence suggesting that squamous hyperplasias do not serve as direct precursors of human papillomavirus-negative vulvar carcinomas.
Kim YT; Thomas NF; Kessis TD; Wilkinson EJ; Hedrick L; Cho KR
Hum Pathol; 1996 Apr; 27(4):389-95. PubMed ID: 8617483
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Morsch R; Rose M; Maurer A; Cassataro MA; Braunschweig T; Knüchel R; Vögeli TA; Ecke T; Eckstein M; Weyerer V; Esposito I; Ackermann M; Niegisch G; Gaisa NT;
BMC Cancer; 2020 Mar; 20(1):230. PubMed ID: 32188412
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva.
Czogalla B; Pham D; Trillsch F; Rottmann M; Gallwas J; Burges A; Mahner S; Kirchner T; Jeschke U; Mayr D; Schmoeckel E
J Cancer Res Clin Oncol; 2020 Mar; 146(3):569-577. PubMed ID: 32025868
[TBL] [Abstract][Full Text] [Related]
37. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva.
Milde-Langosch K; Albrecht K; Joram S; Schlechte H; Giessing M; Löning T
Int J Cancer; 1995 Nov; 63(5):639-45. PubMed ID: 7591279
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression in vulvar cancer: a systematic review and meta-analysis.
Baandrup L; Sand FL; Aalborg GL; Nøttrup TJ; Fiehn AK; Kjaer SK
Histopathology; 2024 Apr; 84(5):742-752. PubMed ID: 38084642
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus infection and cervical cancer in Brazil: a retrospective study.
Cavalcanti SM; Deus FC; Zardo LG; Frugulhetti IC; Oliveira LH
Mem Inst Oswaldo Cruz; 1996; 91(4):433-40. PubMed ID: 9070405
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
Masuda K; Horinouchi H; Tanaka M; Higashiyama R; Shinno Y; Sato J; Matsumoto Y; Okuma Y; Yoshida T; Goto Y; Yamamoto N; Ohe Y
J Cancer Res Clin Oncol; 2021 Jan; 147(1):245-251. PubMed ID: 32705363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
